← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › PROTEIN KINASE INHIBITORS › Human epidermal growth factor receptor 2 (HER2) tyrosine kinase inhibitors
zongertinib
L01EH04
Forms & Strengths
- 150mg and 200mg hard capsules
Adult Dosing
- 150mg orally once daily, 200mg orally once daily for NSCLC patients with EGFR exon20 insertion mutations
Pediatric Dosing
- Safety and efficacy not established in pediatric patients
Indications
- Non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations
Mechanism of Action
- Selective ATP-competitive inhibitor of EGFR tyrosine kinase
Contraindications
- Hypersensitivity to zongertinib or its components
Adverse Reactions
- Diarrhea, rash, nail disorders, stomatitis, fatigue, decreased appetite, edema, interstitial lung disease, QTc interval prolongation
Drug Interactions
- Avoid concomitant use with strong CYP3A4 inhibitors, CYP3A4 inducers may decrease zongertinib exposure
Curated Content: Needs Vetting Before Put to Clinical Use